» Articles » PMID: 32461154

Anaemia and Its Risk Factors and Association with Treatments in Patients with Diabetes: A Cross-sectional Study

Overview
Journal Diabetes Metab
Specialty Endocrinology
Date 2020 May 29
PMID 32461154
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anaemia is frequently seen in patients with diabetes and the main cause is renal failure. At all stages of renal failure, however, the prevalence of anaemia is higher in diabetes patients than expected for their glomerular filtration rate, suggesting that causes of anaemia other than renal failure are at work. The present cross-sectional study was conducted to investigate the possible iatrogenic causes of anaemia in patients with diabetes.

Subjects And Methods: This was a hospital-based cross-sectional study of all patients who had biological and clinical data covering a 2-year period. All had been in contact with the diabetes department either as outpatients or as inpatients mostly for educational purposes. Clinical factors, including type of diabetes, known diabetes complications, treatments received and biological data, were reviewed for their possible involvement in anaemia.

Results: A total of 4145 consecutive patients were included. Anaemia was observed in 1065 (25.7%) of them. Patients with anaemia were more frequently women and those with longer durations of diabetes. Haemoglobin concentrations were decreased, and prevalence of anaemia was increased at all stages of renal failure, already at stage 2, KDIGO classification. Anaemia patients were more frequently taking insulin, antiplatelet agents and renin-angiotensin system blockers (RASBs). After exclusion of patients with specific causes of anaemia, logistic regression analysis of all parameters correlated with anaemia on univariate analysis revealed that anaemia was associated with gender, antiplatelet agents and RASBs.

Conclusion: This study has confirmed that anaemia is frequently seen in diabetes patients and strongly associated with renal failure (already at stage 2). Our observations highlight the adjuvant role of drugs, particularly RASBs, in the risk of anaemia in patients with diabetes.

Citing Articles

Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.

Antoniadou C, Gavriilidis E, Ritis K, Tsilingiris D Metabol Open. 2025; 25:100344.

PMID: 39886103 PMC: 11780985. DOI: 10.1016/j.metop.2024.100344.


The Prevalence and Characteristics of Anemia in Romanian Patients with Type 2 Diabetes: A Cross-Sectional Study.

Gaita L, Timar B, Lazar S, Popescu S, Albai O, Braha A J Clin Med. 2024; 13(23).

PMID: 39685765 PMC: 11641951. DOI: 10.3390/jcm13237306.


Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.

Hu J, Shao S, Tsai D, Chuang A, Liu K, Lai E JAMA Netw Open. 2024; 7(3):e240946.

PMID: 38436955 PMC: 10912959. DOI: 10.1001/jamanetworkopen.2024.0946.


Global Prevalence of Anemia Among Type 2 Diabetic Adult Patients: A Systematic Review and Meta-Analysis.

Arkew M, Asmerom H, Gemechu K, Tesfa T Diabetes Metab Syndr Obes. 2023; 16:2243-2254.

PMID: 37545742 PMC: 10402722. DOI: 10.2147/DMSO.S421851.


Associations of obesity and body shape with erythrocyte and reticulocyte parameters in the UK Biobank cohort.

Christakoudi S, Tsilidis K, Evangelou E, Riboli E BMC Endocr Disord. 2023; 23(1):161.

PMID: 37528422 PMC: 10394790. DOI: 10.1186/s12902-023-01423-1.